[1] |
张凯斐,吕晴晴,孙宁,等. 妊娠期高血压疾病所致早产孕妇的母婴围生结局分析[J/CD]. 中华妇幼临床医学杂志(电子版), 2018, 14(5): 558-565.
|
[2] |
曹泽毅. 中华妇产科学(上册)[M]. 3版. 北京:人民卫生出版社,2014: 154-170.
|
[3] |
李冠琳,杨慧霞. 子痫前期的发病机制及亚型分类[J]. 中华围产医学杂志,2017, 20(12): 899-903.
|
[4] |
胡静,陈沂,高劲松. 早孕期联合筛查预测子痫前期[J]. 中华围产医学杂志,2017, 20(1): 2-6.
|
[5] |
董旭东,朱宝生,焦存仙,等. 妊娠相关血浆蛋白-A预测妊娠期高血压疾病的价值[J/CD]. 中华妇幼临床医学杂志(电子版), 2007, 3(5): 249-251.
|
[6] |
Landers KA, Mortimer RH, Richard K. Transthyretin and the human placenta[J]. Placenta, 2013, 34(7): 513-517.
|
[7] |
Landers KA, McKinnon BD, Li HK, et al. Carrier-mediated thyroid hormone transport into placenta by placental transthyretin[J]. J Clin Endocrinol Metab, 2009, 94(7): 2610-2616.
|
[8] |
钟琳琳,唐卉,陈悦. 重度先兆子痫孕妇发病孕龄与母婴预后的关系[J/CD]. 中华妇幼临床医学杂志(电子版), 2014, 10(4): 521-524.
|
[9] |
刘崇东,鲁琦,张震宇,等. 用蛋白质组学方法分析先兆子痫孕妇血清差异蛋白表达和急性反应蛋白[J]. 首都医科大学学报,2012, 33(1): 20-25.
|
[10] |
中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2015)[J]. 中华妇产科杂志,2015, 50(10): 721-728.
|
[11] |
麻秀丽,鲁琦,张震宇. 妊娠期孕妇血清TTR水平变化及其用于诊断子痫前期的价值[J]. 现代妇产科进展,2016, 25(7): 523-526.
|
[12] |
Patel J, Landers KA, Li H, et al. Ontogenic changes in placental transthyretin[J]. Placenta, 2011, 32(11): 817-822.
|
[13] |
Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis[J]. J Am Coll Cardiol, 2015, 66(21): 2451-2466.
|
[14] |
Wang QS, Liu CD, Zhang ZY. Transthyretin and normal human pregnancy: mini review[J]. Crit Rev Eukaryot Gene Expr, 2016, 26(3): 273-277.
|
[15] |
Landers KA, Li H, Subramaniam VN, et al. Transthyretin-thyroid hormone internalization by trophoblasts[J]. Placenta, 2013, 34(8): 716-718
|
[16] |
McKinnon B, Li H, Richard K, et al. Synthesis of thyroid hormone binding proteins transthyretin and albumin by human trophoblast[J]. J Clin Endocrinol Metab, 2005, 90(12): 6714-6720.
|
[17] |
Mortimer RH, Landers KA, Balakrishnan B, et al. Secretion and transfer of the thyroid hormone binding protein transthyretin by human placenta[J]. Placenta, 2012, 33(4): 252-256.
|
[18] |
Saha S, Chakraborty S, Bhattacharya A, et al. MicroRNA regulation of transthyretin in trophoblast differentiation and intra-uterine growth restriction[J]. Sci Rep, 2017, 7(1): 16548.
|
[19] |
Landers KA, McKinnon BD, Li H, et al. Carrier-mediated thyroid hormone transport into placenta by placental transthyretin[J]. J Clin Endocrinol Metab, 2009, 94(7): 2610-2616.
|
[20] |
Kalkunte SS, Neubeck S, Norris WE, et al. Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model[J]. Am J Pathol, 2013, 183(5): 1425-1436.
|
[21] |
Zhu L, Chen YX, Liu CD. Transthyretin as a novel candidate biomarker for preeclampsia[J]. Exp Ther Med, 2014, 7(5): 1332-1336.
|
[22] |
Roberts JM. Pathophysiology of ischemic placental disease[J]. Semin Perinatol, 2014, 38(3): 139-145.
|
[23] |
杨林东,张承,卞雯雯,等. 预测子痫前期的生物学标志物研究进展[J/CD]. 中华妇幼临床医学杂志(电子版),2015,11(2): 269-273.
|
[24] |
Chen YX, Zhang ZY. Does transthyretin function as one of contributors for preeclampsia?[J]. Med Hypotheses, 2011, 76(1): 8-10.
|
[25] |
Gong LY, Zhu L, Wang SZ, et al. Transthyretin regulates the migration and invasion of JEG-3 cells[J]. Oncol Lett, 2017, 13(3): 1242-1246.
|
[26] |
Kalkunte SS, Neubeck S, Norris WE, et al. Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model[J]. Am J Pathol, 2013, 183(5): 1425-1436.
|
[27] |
Stanek J. Histological features of shallow placental implantation unify early-onset and late-onset preeclampsia[J]. Pediatr Dev Pathol, 2019, 22(2): 112-122.
|
[28] |
Fruscalzo A, Schmitz R, Klockenbusch W, et al. Human placental transthyretin in fetal growth restriction in combination with preeclampsia and the HELLP syndrome[J]. Histochem Cell Biol, 2012, 138(6): 925-932.
|